Para IV Winners and Losers - September 2018
This month’s Para IV developments suggest that there is likely to be benefit to Teva Pharmaceutical Sp Adr (TEVA US) on Vesicare, Soolantra and...
451 Views
Para IV Winners & Losers - May 2018
This month’s Para IV developments suggest that there is likely to be benefit to Amneal Pharmaceuticals Inc (AMRX US) on Lialda, BioQ pharma for...
124 Views
Laurus Labs- Moving up the Value Addition Ladder
Laurus Labs (LAURUS IN) is a research and development driven pharmaceutical company. It is a manufacturer of APIs for ARV, Hepatitis C, oncology...
254 Views
A Storm Will Follow the Lull
Newsflow around the US and state governments' antitrust investigations of the generic drug industry has been quiet since mid-December. Some lull is...
724 Views
IPO Pipeline to Remain Strong as PE Funds, Quasi-Govt Promoters Aim for Portfolio Exits
Primary issuances are expected to remain strong in 2017 following a five-year high in funds raised in 2016 (Rs 220bn) even as Fed rate expectations...
1.3k Views